前瞻性4DCT通气功能回避临床试验中预测肺癌患者肺功能检查变化的变量评估
本研究基于一项II期多中心前瞻性4DCT通气功能回避放疗试验,纳入56例局部晚期肺癌患者,于基线及放疗后3个月获取肺功能检查(FEV1、FVC、FEV1/FVC),采用单因素和多因素线性回归评估临床、剂量及剂量-功能指标对肺功能变化的预测能力。单因素分析显示仅剂量-功能指标和COPD存在可显著预测FEV1下降;多因素分析识别出临床因素联合肺剂量、心脏剂量及剂量-功能指标可预测FEV1和FEV1/FVC变化。结论认为肺剂量-功能指标可预测肺功能变化,验证了降低功能肺剂量以减轻肺功能下降的意义。
要点
- 单因素分析中仅剂量-功能指标和COPD存在可显著预测FEV1下降。
- 多因素分析中临床因素联合肺剂量、心脏剂量及剂量-功能指标可预测FEV1和FEV1/FVC变化。
- 肺剂量-功能指标可预测肺功能变化,验证了降低功能肺剂量的意义。
核心结论
- 数据表明肺剂量-功能指标可预测肺功能检查变化,验证了降低功能肺剂量以减轻肺功能下降的意义,并为未来临床试验提供指导。
研究设计与样本
- 一项II期多中心前瞻性4DCT通气功能回避放疗研究,纳入56例接受放疗的局部晚期肺癌患者。
- 于基线及放疗后3个月获取肺功能检查,包括FEV1、FVC和FEV1/FVC。
- 采用单因素和多因素线性回归评估患者、临床、剂量(肺和心脏)及剂量-功能指标对肺功能检查变化的预测能力。
主要发现
- 单因素分析显示仅剂量-功能指标和COPD的存在在预测FEV1下降中显著(p<0.05)。
- 多因素分析识别出临床因素(免疫治疗状态、胸部合并症、吸烟状态和年龄)联合肺剂量、心脏剂量及剂量-功能指标可预测FEV1和FEV1/FVC变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Functional avoidance radiotherapy uses functional imaging to reduce pulmonary toxicity by designing radiotherapy plans that reduce doses to functional regions of the lung. A phase-II, multi-center, prospective study of 4DCT-ventilation functional avoidance was completed. Pre and post-treatment pulmonary function tests (PFTs) were acquired and assessed pulmonary function change. This study aims to evaluate which clinical, dose and dose-function factors predict PFT changes for patients treated with 4DCT-ventilation functional avoidance radiotherapy. MATERIALS AND METHODS: 56 patients with locally advanced lung cancer receiving radiotherapy were accrued. PFTs were obtained at baseline and three months following radiotherapy and included forced expiratory volume in 1-second (FEV1), forced vital capacity (FVC), and FEV1/FVC. The ability of patient, clinical, dose (lung and heart), and dose-function metrics (metrics that combine dose and 4DCT-ventilation-based function) to predict PFT changes were evaluated using univariate and multivariate linear regression. RESULTS: Univariate analysis showed that only dose-function metrics and the presence of chronic obstructive pulmonary disease (COPD) were significant (p<0.05) in predicting FEV1 decline. Multivariate analysis identified a combination of clinical (immunotherapy status, presence of thoracic comorbidities, smoking status, and age), along with lung dose, heart dose, and dose-function metrics in predicting FEV1 and FEV1/FVC changes. CONCLUSION: The current work evaluated factors predicting PFT changes for patients treated in a prospective functional avoidance radiotherapy study. The data revealed that lung dose- function metrics could predict PFT changes, validating the significance of reducing the dose to the functional lung to mitigate the decline in pulmonary function and providing guidance for future clinical trials.
引用
- Ghassemi N, Castillo R, Castillo E, et al. Evaluation of variables predicting PFT changes for lung cancer patients treated on a prospective 4DCT-ventilation functional avoidance clinical trial. Radiother Oncol. 2023. PMID: 37516361. doi:10.1016/j.radonc.2023.109821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。